Use of Recombinant DNA Techniques for the Production of a More Effective Anthrax Vaccine
Abstract
The overall goal of the present research is to construct safe and effective human anthrax vaccine using recombinant DNA techniques. During the course of this contract, we have isolated and characterized each of the Bacillus anthracis toxin genes. Although the PA (pag) gene was cloned and sequenced by researchers in the Bacteriology Division of USAMRIID, the cloning and characterization of the EF (cya) and LF (lef) genes were performed in my laboratory. In addition, DNA sequence determinations for the cya and lef (unpublished data of author) genes have also been completed in my laboratory. We have prepared an improved method for the isolation of large quantities of pX01 and pX02 from B. anthracis strains. Restriction enzyme cleavage maps for these plasmids have been constructed. We have initiated mutagenesis procedures for the modification of each of the toxin genes and these mutants are being tested for biochemical activity. In addition, wild-type and mutant toxin genes are being inserted into B. subtilis to produce larger quantities of these proteins for biochemical purposes and for vaccine testing. However, we have not yet placed mutant toxin genes back into B. anthracis, although the wild type PA and EF genes have been transferred.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 31, 1988
- Accession Number
- ADA212330
Entities
People
- Donald L. Robertson
Organizations
- Brigham Young University